Healthcare Industry News: Terumo
News Release - February 17, 2016
Terumo Cardiovascular Group Introduces the CAPIOX(R) FX Advance OxygenatorANN ARBOR, Mich., Feb. 17, 2016 -- (Healthcare Sales & Marketing Network) -- Terumo Cardiovascular Group (Terumo CV Group) introduces the newest addition to the CAPIOX® Oxygenator portfolio – the CAPIOX FX Advance Oxygenator. The CAPIOX FX Advance replaces the current CAPIOX FX15 and FX25 line of oxygenators manufactured in Elkton, Maryland.
"Terumo Cardiovascular Group was the first company to introduce a hollow fiber membrane oxygenator and since then, has led the way in oxygenator innovation and quality," says Arik Anderson, President, Perfusion and Surgical Devices Division. "The FX Advance Oxygenator builds on that innovation and represents Terumo's continuing investment in its CAPIOX oxygenator portfolio."
Enhancements to the CAPIOX FX Advance include improved flow dynamics with an increased blood flow rate on the 3,000 mL reservoir – available on the FX15 Advance Oxygenator – and a lower minimum operating level on the 4,000 mL reservoir – available on the FX15 and FX25 Advance Oxygenators. The CAPIOX FX Advance helps clinicians further reduce prime volume and lower hemodilution, allowing them to choose a smaller, lower prime oxygenator for even more patients.
"Terumo's Elkton, Maryland, facility has established a reputation as an industry leader in oxygenator development and manufacturing," says Lou Peticca, Elkton Facility Plant Manager. "All Elkton Associates know the importance of their work. We're in the business of saving lives, and everything we do has that objective in mind."
To preview the CAPIOX FX Advance oxygenator, visit the Terumo booth at these 2016 U.S. conferences:
- CREF – February 24-27
- AmSECT – March 15-19
- Sanibel Symposium – April 20-23
- American Association for Thoracic Surgery (AATS) – May 14-18
- Mechanisms of Perfusion – May 19-22
About Terumo Cardiovascular Group
Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4.6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and is a component of the Nikkei, Japan's leading stock index.
Terumo® and CAPIOX® are registered trademarks of Terumo Corporation
©2016 Terumo Cardiovascular Systems Corporation. February 2016
Source: Terumo Cardiovascular
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.